Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
XPHvsARKGETF Comparison
SPDR S&P Pharmaceuticals ETF (XPH) belongs to the US Health Care segment. ARK Genomic Revolution ETF (ARKG) is part of the BioTech & Genomics segment. Both ETFs have the same top 3 sector exposures: and Health Care. XPH is less expensive with a Total Expense Ratio (TER) of 0.35%, versus 0.75% for ARKG. XPH is down -1.12% year-to-date (YTD) with +$88M in YTD flows. ARKG performs worse with -4.22% YTD performance, and -$14M in YTD flows. Run a side-by-side ETF comparison of XPH and ARKG below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
XPH vs ARKG performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH ARKG | -3.45%-3.97% | -1.36%-10.24% | -1.12%-4.22% | +29.22%+27.40% | +42.98%+1.75% | +9.16%-68.08% |
| Flows | XPH ARKG | +$12M-$69M | +$95M-$81M | +$88M-$14M | +$111M-$206M | +$48M-$635M | +$36M-$2.75B |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH ARKG | +20.33%+39.15% | +23.08%+44.66% | +19.01%+42.31% | +20.26%+45.26% |
| Max drawdown | XPH ARKG | -5.97%-19.50% | -17.10%-23.94% | -23.45%-51.98% | -33.10%-80.33% |
| Max drawdown duration | XPH ARKG | 14d47d | 140d77d | 322d965d | 1706d1821d |
XPH | ARKG | |
Last sale 3/11/2026 at 7:59 PM | $55.48 | $27.00 |
| Previous close 03/11/2026 | $55.67 | $27.93 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XPH | ARKG | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XPH | ARKG | |
|---|---|---|
| Last price | $55.48 | $27.00 |
| 1D performance | -0.34% | -3.33% |
| AuM | $313.37 M | $1.11 B |
| E/R | 0.35% | 0.75% |
XPH | ARKG | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | SPDR | Ark Investment |
| Benchmark | S&P Pharmaceuticals Select Industry Index | - |
| N° of holdings | 49 | 30 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | April 2, 2019 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the XPH and ARKG ETFs performed in 2026?
As of March 11, 2026, XPH is down -1.12% year-to-date (YTD), while ARKG has lost -4.22%. That puts XPH better performer ahead so far this year.
Which ETF is attracting more investor money: XPH or ARKG?
Year-to-date, the XPH ETF saw +$88M in flows, compared to -$14M for ARKG.
Which ETF is more volatile: XPH or ARKG?
Over the past year, XPH had a volatility of 23.08%, while ARKG experienced 44.66%.
Which ETF is bigger: XPH or ARKG?
As of March 11, 2026, XPH holds $313.37 M in assets under management (AUM), while ARKG manages $1.11 B.
What sectors do the XPH and ARKG ETFs invest in?
XPH leans toward sectors like Health Care. Meanwhile, ARKG focuses on Health Care.
What are the top holdings of the XPH ETF and ARKG ETF?
XPH top holdings include LIQUIDIA CORPORATION, US55287L1017 and AXSOME THERA CMN STK. ARKG holds in its top three: CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC.
Which ETF is more diversified: XPH or ARKG?
XPH holds 57 securities with 32.4% of its assets in the top 15. ARKG has 30 securities and a top 15 weight of 63.79%.
Donald Trump’s Executive Orders: ETF Bulls and Bears
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
Biotech ETFs – Investing in Health Innovation
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
